Eroton (sildenafil) tablets 50 mg. №4

Description

Eroton 50 mg Composition
active substance: sildenafil;

1 tablet contains sildenafil citrate in doses equivalent to 50 mg of sildenafil;

excipients: calcium hydrogen phosphate dihydrate, microcrystalline cellulose, copolyvidone, colloidal silicon dioxide, talc, magnesium stearate, croscarmellose sodium, potato starch.

Eroton 50 mg Dosage form
Pills.

Basic physical and chemical properties: tablets of white color, biconvex, hexagonal (“HEXAGON” form), marked “F” on both sides.

Pharmacotherapeutic group
Drugs used for erectile dysfunction. Sildenafil ATX code G04B E03.

Pharmacodynamics
Mechanism of action. Sildenafil is an oral drug used to treat erectile dysfunction in men. With sexual arousal, the drug restores reduced erectile function by increasing blood flow to the penis.

The physiological mechanism that leads to an erection, including the release of nitric oxide (NO) in the corpora cavernosa during sexual arousal. The released nitric oxide activates the enzyme guanylate cyclase, which stimulates an increase in the level of cyclic guanosine monophosphate (cGMP), which, in turn, causes relaxation of the smooth muscles of the corpora cavernosa, promoting blood flow.

Sildenafil is a potent and selective inhibitor of cGMP-specific phosphodiesterase 5 (PDE-5) in the corpora cavernosa, where PDE-5 is responsible for the breakdown of cGMP. The effects of sildenafil on erection are peripheral. Sildenafil does not have a direct relaxing effect on isolated human cavernous bodies, but powerfully enhances the relaxing effect of NO on this tissue. When the metabolic pathway NO / cGMP is activated, which occurs during sexual stimulation, inhibition of PDE5 by sildenafil leads to an increase in the level of cGMP in the corpora cavernosa. Thus, in order for sildenafil to cause a pharmacological effect, sexual arousal is necessary.

Impact on pharmacodynamics. In vitro studies have shown that sildenafil is selective for PDE-5, which is actively involved in the process of erection. The effect of sildenafil on PDE-5 is more potent than on other known phosphodiesterases. This effect is 10 times more powerful than the effect on PDE6, which is involved in the processes of phototransformation in the retina. When using the maximum recommended doses, the selectivity of sildenafil for PDE5 is 80 times higher than its selectivity for PDE1, 700 times higher than for PDE2, PDE-3, PDE4, PDE7, PDE8, PDE9, PDE10 and PDE11. In particular, the selectivity of sildenafil for PDE5 is 4000 times higher than its selectivity for PDE-3, a cAMP-specific isoform of PDE, which is involved in the regulation of cardiac contractility.

Eroton 50 mg Indications
The drug is recommended for men with erectile dysfunction, which is defined as the inability to achieve or maintain an erection of the penis necessary for successful intercourse.

For the effective action of the drug, sexual arousal is necessary.

Contraindications
Hypersensitivity to sildenafil or any of the excipients of the drug;
simultaneous use with nitric oxide donors (such as amyl nitrite) or nitrates in any form – sildenafil affects the pathways of nitric oxide / cyclic guanosine monophosphate (cGMP) metabolism and potentiates the hypotensive effect of nitrates;
the simultaneous use of PDE-5 inhibitors (including sildenafil) with guanylate cyclase stimulants such as riociguat is contraindicated because it can lead to symptomatic hypotension (see Section “Interaction with other medicinal products and other types of interactions”);
conditions in which sexual activity is undesirable (severe cardiovascular disorders such as unstable angina or severe heart failure);
the drug is contraindicated in patients who have lost vision in one eye due to non-arterial anterior ischemic neuropathy of the optic nerve, regardless of whether this pathology is associated with previous use of PDE-5 inhibitors or not;
the presence of diseases such as severe liver dysfunction, arterial hypotension (blood pressure below 90/50 mm Hg), recent stroke or myocardial infarction, and hereditary degenerative retinal diseases such as retinitis pigmentosa (such patients may have genetic disorders Retinal PDE) – the safety of sildenafil has not been studied in these patient subgroups.